Skip to content
TFS TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO
Request a proposal

Full Service trials

Solutions Full Service trials

One team carries your trial, from protocol to database lock

We plan, run and close your clinical trial with one team that stays on it the whole way. There are no hand-offs between vendors, and no new group to re-brief halfway through.

Our therapeutic leads can make decisions themselves. When something shifts, the plan changes on the call, not three approvals later.
Request a proposal Talk to our team

+500

Professionals

+1800

Clinical trials completed

88%

Team retention

How we secure your clinical pathway

Clinical continuum

Built-in flexibility, from a single CRA to full global trials.

Strategic resourcing, FSP and full-service clinical development, working as one team. Scale capacity across 40 countries, eliminating vendor handoffs while preserving protocol knowledge in the room the whole way through.

Therapeutic depth

Fast decisions through specialized clinical depth.

We restrict our focus to five complex therapeutic areas. Our specialized leads theyhold direct decision-making authority, fast-tracking approvals and solving site bottlenecks with scientific authority.

Teams that stay

True peers, driven by scientific urgency.

TFS holds an 88% retention rate, 8 points above the industry average. That means the senior scientific peer who joins your study is still there at database lock.

Trial security

Risk flagged early. Execution made visible.

Rooted in our Swedish heritage, we bring disciplined methodology and transparent communication to every study. We deliver real-time data integrity, flag protocol issues before they cost you time, and maintain regulatory compliance at every milestone.

Advancing your clinical development from Phase I to III

Contact

Early Phase I–II

Guided by senior medical and regulatory advisors, we build customized strategies to navigate early clinical development with absolute operational efficiency.

— First-in-human and proof-of-concept studies
— Micro-dosing— Single and multiple ascending dose (SAD/MAD)
— Drug-drug and food-drug interactions
— Flexible trial design (e.g., adaptive, basket/umbrella)
— Biosimilarity and bioequivalence
— Regulatory strategy and submission (CTA/ITA, PIP, IND, PMA/510k)
— Pharmacokinetics/Pharmacodynamics (PK/PD)
— PET imaging
— Bioanalytical support
— Pediatric populations
— Elderly populations
— Rare disease and orphan indications
— Medical devices
— Direct executive oversight through our TFS governance model

Phase II/III

We provide comprehensive operational capabilities for pivotal studies. You receive the same level of scientific dedication and attention to detail, regardless of your asset size or therapeutic area.

— Dedicated project manager assigned in agreement with your team
— Continuous and transparent communication throughout the trial
— Comprehensive project kickoff and planning with built-in flexibility for protocol changes
— Accelerated study start-up through our trusted investigator site network
— Robust EDC, CTMS, and clinical analytics integration to ensure data integrity
— Real-time metrics review via our customer portal

Securing the path for sponsors’ science.

View all

The resourcing decision : Full-service, FSP or specialist. Which one actually fits your programme?

Read case study

The new endpoints reshaping oncology trial design

Read case study

Juneteenth and the next chapter of medicine

Read case study

This Pride Month see the life behind every number

Read case study

Global presence designed for local agility

International scale, deep local roots

We have built our structure by integrating established clinical teams across key markets, rather than handing off trials to unknown third parties. Operating directly on the ground allows us to navigate local regulations, streamline ethics approvals and keep recruitment on track.

Australia France Hungary Italy Norway Portugal Sweden United Kingdom Belgium Czech Republic Finland Germany Israel Netherlands Poland Spain Switzerland United States Canada Denmark

Updates to keep your trials
moving forward.

News VERIGRAFT and TFS HealthScience partner on pivotal Phase II/III trial of personalized tissue-engineered vein for chronic venous insufficiency
Read news
News Our 2025 sustainability year in review: the highlights
Read news
News Europe's clinical development landscape: does the EU hold a busted flush or a full house?
Read news
News Expanding the Frontiers of Neuroscience: TFS Strengthens Its Gene Therapy Portfolio in Neurodegenerative Diseases
Read news
View all

Clinical operations & outsourcing FAQs.

What clinical outsourcing models does TFS provide?
We deliver three modular frameworks under a single contract: Strategic Resourcing, Functional Service Provider (FSP), and Full-Service Trials. This model elasticity allows you to scale clinical capacity fluidly as your pipeline demands, eliminating vendor handoffs.

What is the geographic footprint and reach of TFS?
Founded in Lund, Sweden, we operate as a global CRO with active regulatory and clinical reach across 40 countries. We combine comprehensive multi-region execution with specialized infrastructure and investigator networks across Europe and the Nordics.

How does TFS maintain clinical study continuity?
We maintain an industry-leading CRA turnover rate of 14%, significantly outperforming the 20% sector average. This team stability ensures consistent protocol knowledge, reduces management burden, and protects your data integrity.

Which therapeutic areas does TFS specialize in?
We concentrate our medical, clinical, and regulatory capabilities exclusively within five core areas: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology, backed by a track record of 1,800+ completed trials.